{
  "docId": "019de072-8046-72ee-8797-71c9ff7422eb",
  "docSlug": "98d74c454dfdfefd8fb9993ff5213b70",
  "documentTitle": "Hillevax | IPO Presentation Deck | 24 slides",
  "authorId": "hillevax",
  "authorName": "Hillevax",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 8,
  "pageCount": 24,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide highlights the clinical validation and market opportunity for the lead asset.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-8046-72ee-8797-71c9ff7422eb/8",
  "deckHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb",
  "deckJsonHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb.json",
  "deckAnchorHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.35,
        "y": 0.2
      },
      "kind": "callout",
      "text": "HIL-214 (formerly TAK-214)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7957cf25-40fe-4f32-b1e3-624439eeaf62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.7,
        "y": 0.15
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12b2590a-f1c9-491c-9ee9-dddaf62d52a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "list",
      "text": "Bivalent VLP vaccine\nPotential to be first vaccine approved for norovirus-related illness\nLicensed from Takeda\n9 Phase I & II studies completed in >4,500 subjects\nClinical PoC demonstrated in adult Phase IIb study\nMulti-billion dollar commercial potential",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7128f7c-9c9b-4c4c-9b2e-a53fd86874cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Potential breakthrough for the prevention of norovirus-related illness",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83e9e30c-cdaa-4f5b-a0ba-f71f5bda4aaa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 8,
      "beatId": "03cc61d7-273b-4594-831c-1971a284d9c4",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slide 8 presents HIL-214 as a potential breakthrough solution",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}